About Dr Renata Szyszka

KEY SKILLS & RESUME:

  • Leadership, Strategic Vision
  • Biotechnology & Pharmaceutical R&D
  • Rare Disease Therapeutics
  • Stakeholder Engagement & Networking
  • Mass Spectrometry & Analytical Chemistry
  • Education & Mentoring

Renata Szyszka, Ph.D., is responsible for global coordination and strategic development of therapies for Leber’s congenital amaurosis (LCA). She is a qualified scientist interested in integrating basic research and foundational studies with clinical implementation and post-market approval.

The University of Gdansk in Poland awarded Dr. Szyszka an MS with honors in 2003, and Drexel University in the United States awarded her a Ph.D. in analytical chemistry (MALDI TOF-MS) in 2012. She specializes in developing exploratory technologies for the treatment of rare diseases and has extensive experience in the field of advancing translational sciences.
At the primary research and development facility for Arkema in King of Prussia, Pennsylvania, she began her career in 2003 as a research intern. Later, she relocated to Polpharma S.A, the current market leader in generic pharmaceuticals, where she gained experience as an analytical chemist. There, she worked until 2007. She subsequently made the decision to attend Drexel University in Philadelphia to finish her Ph.D., where she worked up until 2012. Since then, she has held leadership and scientific positions with both established corporations and start-ups, such as Cordis Corporation- A Johnson and Johnson Company (PA, USA), Pharmaceutical Research Institute (PL), ProQR Therapeutics B.V. (NL), and Pall Life Sciences (UK).
She worked arduously and devotedly to pave her way to success. She made a change and accepted the role of Owner and Founder at E&ILCA, an enterprise she created and has been growing since 2016. Global Executive Leadership and a strong drive for research and innovation rank among her strongest qualities. She builds enterprises from the ground up. She successfully transforms enormous challenges into wonderful possibilities thanks to her entrepreneurial mindset. Personally humble and firmly planted on the earth.

While you may not personally know anyone who is blind, you do now. Leber’s congenital amaurosis (LCA) is an inherited retinal disorder that causes severe vision impairment in infants and young children. Unfortunately, diagnosis is often delayed due to a lack of awareness, and, as of now, there is no cure.

I firmly believe that there is a treatment for every illness, and what makes me an integral part of this vast ecosystem dedicated to the study of life is raising awareness among Key Opinion Leaders (KOLs) about what it truly means to experience blindness.

  • We position ourselves as forward-thinking advocates of innovation.
  • We remain attuned to our genuine emotional connections.
  • We emphasize the vital importance of education and braille literacy for blind individuals.

Visually healthy people have the unique opportunity to approach scientific challenges from fresh perspectives, generating innovative solutions. Our ability to balance high legal and corporate standards with empathy allows us to become exceptional innovators throughout the entire process of commercializing breakthrough medications.

PROFESSIONAL RECOGNITION & PERSONAL DEVELOPMENT